SCHEMBL19848367

SCHEMBL19848367

COc1ccc2c(c1)ncn2N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.59
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 2/20 0.51
HTT P42858 4/20 0.46
HPGD P15428 2/20 0.46
MAPK1 P28482 1/20 0.46
MAPK10 P53779 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
KDR P35968 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 2/20 0.42
POLB P06746 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848089 0.86 ALDH1A1 (0.58) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL230452 0.80 FGFR1 (0.59) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL4580483 0.79 FGFR1 (0.58) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL19911344 0.77 FGFR1 (0.56) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL11054271 0.77 FGFR1 (0.56) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL6758619 0.76 NPC1 (0.65) FGFR1ALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL18937429 0.76 FGFR1 (0.55) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL19848228 0.76 FGFR1 (0.55) FGFR1ALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL20489183 0.76 FGFR1 (0.52) FGFR1ALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL15241833 0.76 FGFR1 (0.54) FGFR1ALDH1A1SMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
EP-3279997-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2018-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 FGFR1 1543/4885ALDH1A1 3497/4885SMN1; SMN2 3476/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 FGFR1 1543/4885ALDH1A1 3497/4885SMN1; SMN2 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.